

novocure<sup>®</sup>

patientforward



# forward-looking statements

In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Novocure's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.


The statements contained in this presentation are made as at the date of this presentation, unless some other time is specified in relation to them, and service of this presentation shall not give rise to any implication that there has been no change in the facts set out in this presentation since such date. Nothing contained in this presentation shall be deemed to be a forecast, projection or estimate of the future financial performance of Novocure, except where expressly stated.

As of the date of this presentation, Optune Gio is FDA-approved for the treatment of adults with supratentorial glioblastoma (GBM). Optune Lua is FDA-approved for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) and for the treatment of adults with malignant pleural mesothelioma or pleural mesothelioma (MPM), respectively, and the approval for use in other indications is not certain. Novocure can provide no assurances regarding market acceptance of Optune Gio or Optune Lua or their successful commercialization and can provide no assurances regarding the company's results of operations or financial condition in the future. This presentation is for informational purposes only and may not be relied upon in connection with the purchase or sale of any security.



together with our patients,  
we strive to extend survival  
in some of the most  
aggressive forms of cancer



# Tumor Treating Fields (TTFields) target the electrical properties of cancer cells



TTFields are delivered through a portable, wearable medical device



# strong foundation and building towards profitability



approved and  
reimbursed  
IN MAJOR GLOBAL MARKETS

>4,000

GLOBAL ACTIVE PATIENTS  
ON THERAPY

NCCN Category 1  
GUIDELINE RECOMMENDATION

\$605M

2024 NET REVENUE

\$210M  
2024 R&D INVESTMENTS

intellectual property  
ROBUST PORTFOLIO WITH  
ONGOING DEVELOPMENTS

# significant achievements in 2024

## GROW GBM

- \$605m net revenue
- Successful launch in France
- Improved U.S. approval rates

## LAUNCH LUNG

- PMA received
- U.S. launch
- 52 new Rx; 20 active patients\*

## DELIVER PIPELINE

- Phase 3 METIS successful
- Phase 3 PANOVA-3 successful
- Flex array PMA suppl. approved



entering a new era with  
expanding oncology platform  
driven by 3 positive phase 3 trials

FIRST  
INDICATION  
IN GBM


3 POSITIVE TRIALS  
IN NEW  
INDICATIONS

MULTI-  
INDICATION  
PLATFORM  
THERAPY



# extended survival in newly diagnosed GBM

## EF-14 PHASE 3 CLINICAL TRIAL OVERALL SURVIVAL




	Optune Gio + TMZ (n=466)	TMZ alone (n=229)
Median OS from randomization (months)	20.9	16.0
Log-rank <i>P</i> -value	<0.001	
HR (95% CI)	0.63 (0.53–0.76)	
Median OS from diagnosis (months)	24.5	19.8

**NEXT STEPS:**  
Potentially label expanding  
TRIDENT, KEYNOTE D58 trials

# extended survival in metastatic NSCLC

## LUNAR PHASE 3 CLINICAL TRIAL OVERALL SURVIVAL




	Optune Lua + SOC (n=137)	SOC alone (n=139)
Median OS (months)	13.2	9.9
Log-rank <i>P</i> -value	0.035	
HR (95% CI)	0.74 (0.56–0.98)	
3-year survival (95% CI)	18% (11-27)	7% (2-15)

**NEXT STEPS:**  
U.S. launch underway; global applications under review

# extended survival together in mNSCLC with ICI

## LUNAR PHASE 3 CLINICAL TRIAL OVERALL SURVIVAL IN ICI COHORT




	TTFIELDS + ICI (n=66)	ICI alone (n=68)
Median OS (months)	18.5	10.8
Log-rank <i>P</i> -value	0.03	
HR (95% CI)	0.63 (0.41–0.96)	
3-year survival (95% CI)	27% (15–27)	9% (3–21)

**NEXT STEPS:**  
Potentially label expanding  
LUNAR-2 trial

# extended time to progression in brain metastases

## METIS TRIAL TIME TO INTRACRANIAL PROGRESSION



	TTFields + BSC (n=149)	BSC alone (n=149)
Median TTIP (months)	<b>21.9</b>	<b>11.3</b>
Log-rank <i>P</i> -value	0.0158	
HR (95% CI)	0.667 (0.480–0.927)	

**NEXT STEPS:**  
Global regulatory filings underway

# extended survival in unresectable, locally advanced pancreatic cancer

TTFIELDS arm demonstrated...




(HR=0.819, p=0.039)

## NEXT STEPS:

Data presentation at upcoming medical congress; global regulatory filings underway

# new indications significantly expand eligible patient population

## U.S. ANNUAL DIAGNOSES OF ON-LABEL PATIENTS SEEKING THERAPY



**7x**  
EXPANSION IN  
TOTAL  
ADDRESSABLE  
MARKET FROM NEW  
INDICATIONS

# 2025 anticipated commercialization milestones



**LUNAR**  
Lung Cancer

- Generate U.S. demand, pursue reimbursement
- Obtain PMDA approval, Japan launch
- Obtain CE Mark, Germany launch



**METIS**  
Brain Metastasis

- Publish in peer-reviewed journal
- Submit regulatory applications in U.S., EU and Japan



**PANOVA-3**  
Pancreatic Cancer

- Present data at key congress
- Publish in peer-reviewed journal
- Submit regulatory applications in U.S., EU and Japan

# 2025-2026 anticipated clinical development milestones

	TRIAL	TTFIELDS +	PHASE 2	PHASE 3	APPROVED
<b>CNS indications</b>	glioblastoma	EF-14	TMZ	✓	
		TRIDENT	TMZ + radiation	DATA IN 2026	
		KEYNOTE D58	TMZ + pembrolizumab	enrolling	
	brain metastases	EF-11	monotherapy (recurrent GBM)	✓	
		METIS	monotherapy	SUBMISSION IN 2025 Breakthrough Designation	
<b>torso indications</b>	non-small cell lung cancer	LUNAR	docetaxel or PD-L1 inhibitor (2L)	✓	
		LUNAR-2	pembrolizumab + platinum (1L)	enrolling	
		LUNAR-4	pembrolizumab (2L retreatment)	enrolling	
	mesothelioma	STELLAR	pemetrexed + cisplatin/carboplatin	✓	
	pancreatic cancer	PANOVA-3	nab-paclitaxel + gemcitabine (LAPC)	SUBMISSION IN 2025 Breakthrough Designation	
		PANOVA-4	atezolizumab + nab-paclitaxel + gemcitabine (MPC)	DATA IN 2026	



striving to extend survival for as many patients with aggressive cancers as we can

3

**FUTURE EXPANSION**

Advance label-expanding clinical trials, investment in platform

2

**OPPORTUNITIES ON THE HORIZON**

Drive new indications (PANOVA; METIS), further product development


1


**NEAR-TERM OPPORTUNITIES**

Increase GBM penetration, launch lung, launch new arrays

**TODAY**

4,126 active patients





DRIVE

COURAGE

TRUST

patientforward

EMPATHY

INNOVATION

FOCUS

